Functional Cure (Chronic Viral Infection)¶
Recognize sustained disease-specific control of a chronic viral infection without claiming that every persistent viral source has been eliminated.
Core Idea¶
A functional cure in chronic viral infection is a disease-specific endpoint of sustained control without requiring proof that every viral source has been eliminated. The report must say which markers show control, for how long, and under what treatment context. In HIV, researchers distinguish prolonged control without ordinary antiretroviral therapy (ART) from a classical cure that eliminates all virus-carrying cells. In chronic hepatitis B (HBV), researchers use sustained virological response and disappearance of hepatitis B surface antigen (HBsAg) after finite treatment. These share the control-versus-eradication distinction, but not one assay or threshold.[ref-ca2fb6317fe1][ref-4388e5a179ee][^ref-bafcc291f963]
Control does not imply a detectable reservoir in every person, either. The VISCONTI HIV group had very low residual virus; in Gan and colleagues' HBV cohort, intrahepatic cccDNA was detected in 35 of 48 functionally cured participants and not detected under the study assay in 13. Neither a positive finding in some cases nor a negative assay in others permits a universal eradication conclusion. Later recurrence is possible, not inevitable.[ref-ca2fb6317fe1][ref-bafcc291f963]
Scope of Application¶
This entry describes chronic-viral-infection research endpoints, not a treatment procedure or an individual's prognosis. VISCONTI's selected HIV post-treatment controllers had years of observed viremia control after ART. NIH notes that the broader ART-free remission goal may still involve intermittent or ongoing non-ART interventions, so ART-free must not be expanded to “no intervention whatsoever.”[ref-ca2fb6317fe1][ref-4388e5a179ee]
Gan and colleagues classify chronic-HBV functional cure through HBsAg loss and virological response after finite therapy. Some in their cohort had detectable cccDNA and some had later HBsAg seroreversion. CML treatment-free molecular remission is a structurally suggestive but distinct disease-specific endpoint in its original paper, not an interchangeable HIV/HBV criterion or established alias of this scoped identity.[ref-bafcc291f963][ref-d901d3eb5120]
Clarity¶
The abstraction separates observable disease control from proof of biological eradication. It also distinguishes the absence of ordinary disease-suppressive therapy from the absence of all possible interventions, and bounded follow-up from permanent cure. In the HBV study, HBsAg seroreversion occurred in seven participants, but virological relapse in two; those are not identical outcomes.[ref-4388e5a179ee][ref-bafcc291f963]
Manages Complexity¶
Instead of collapsing all viral tests into one word, the endpoint asks five compact questions: which virus, which markers, what observation duration, what treatment context, and what stronger eradication claim is deliberately withheld? HIV viremia/reservoir observations and HBV HBsAg/cccDNA observations fill different slots. This preserves a meaningful control result without turning a favorable serum result into proof about every hidden compartment.[ref-ca2fb6317fe1][ref-bafcc291f963]
Abstract Reasoning¶
When encountering a functional-cure claim, identify the exact observed endpoint before inferring mechanism or permanence. VISCONTI's prolonged post-ART control is compatible with a low residual HIV reservoir; Gan's sustained HBV marker response is compatible with detectable cccDNA in some participants. A single negative assay cannot prove absence of every viral source, and a later recurrence changes the durability judgment without showing that every other case must recur.[ref-ca2fb6317fe1][ref-bafcc291f963]
Knowledge Transfer¶
The distinction between functional control and sterilizing elimination transfers between HIV and HBV research. Their markers, treatment contexts and time windows do not. A broader portable control-versus-eradication prime is an unadmitted future question. The frozen HIV-remission request is retained as provenance, not automatically made an alias for all uses of this broader reframe; CML treatment-free remission remains a separate terminology question.[ref-4388e5a179ee][ref-bafcc291f963][^ref-d901d3eb5120]
[^ref-ca2fb6317fe1]: Asier Sáez-Cirión et al., “Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy: ANRS VISCONTI Study”, PLoS Pathogens 9 (2013), e1003211, original abstract and Figures 1, 4 and 5. [^ref-bafcc291f963]: Weiqiang Gan et al., “Reduction in Intrahepatic cccDNA and Integration of HBV in Chronic Hepatitis B Patients with a Functional Cure”, Journal of Clinical and Translational Hepatology 11 (2023), original Abstract, Introduction and Results Table 1. [^ref-4388e5a179ee]: National Institutes of Health / NIAID, “Fauci: HIV remission free of antiretroviral therapy is a feasible goal”, 25 July 2018, original institutional statement. [^ref-d901d3eb5120]: David M. Ross et al., “Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells”, Leukemia 32 (2018), original publisher abstract, used only as a comparator.
Neighborhood in Abstraction Space¶
Functional Cure (Chronic Viral Infection) sits in a sparse region of the domain-specific corpus (90th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.
Family — Clinical Trial Design & Drug Safety (22 abstractions)
Nearest neighbors
- Biodistribution — 0.81
- Clinical Endpoint — 0.80
- Spectrum Bias — 0.80
- Antimicrobial Spectrum — 0.79
- Surrogate Endpoint — 0.79
Computed from structural-signature embeddings · 2026-10-08